This article is protected by copyright. All rights reserved Dear Editor, the intra-operative control of surgical dissection still continues to be a matter of interest 1 . The correct plane of dissection sometimes is hardly to be defined and a realtime pathological examination could be useful to assess if benign or malignant prostate tissue still remains at the prostatic fossa [1] [2] [3] [4] .
Frozen section and NeuroSAFE have been developed to this purpose [1] [2] [3] [4] . These techniques require a fully equipped laboratory, a pathologist inside the institution and, overall, take >30 minutes. These evidences have limited the diffusion of the NeuroSAFE, which is currently performed in facilities with a dedicated setup.
A superimposed 3D-imaging represents another solution to make the surgeon confident with the plane of dissection 5 . However, as for the NeuroSAFE, not all institutions can afford such a technological advance and, it relies on mpMRI, whose sensitivity to detect extracapsular extension (ECE) is generally low 6 .
Moreover, the surgeon could have concerns about the consistency of the prostate also in an imaging-safe area. A possible inadvertent dissection into glandular tissue may happen and the knowledge of persistent benign prostate tissue at margin of dissection is of importance
Given the importance of a tailored and controlled dissection, the aim of the research is to test the ability of a novel technique, the fluorescence confocal microscopy (FCM) to detect residual prostate tissue in the peri-prostatic environment differentiating it from extraprostate soft tissues.
Ex-vivo FCM (VivaScope®2500M-G4; Mavig GmbH, Caliber I.D.; RochesterNY,USA) is an optical technology allowing examination of freshly excised tissue using fluorescence and reflectance modalities, providing a similar-histological view of tissues in few minutes. We previously tested the level of agreement between FCM and conventional hematoxylin-eosin (HE) pathway to discriminate between prostate cancer (PCa) and normal prostatic tissue, finding an agreement of 91% (Cohen'sK =0,75) 8 . This trial 8 was designed as an exploratory study with samples obtained by 18G-biopsies of a prostate specimen, in order to test the feasibility of prostate tissue reading with FCM.
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We are currently evaluating FCM in a real-life setting, the intra-operative analysis of periprostatic tissue retrieved at suspect areas. To this purpose, we sought to explore the level of agreement between FCM and HE in discriminating patterns typical of peri-prostatic tissue.
Twenty patients elected to partial or full nerve-sparing RALP (January to June 2019) were enrolled in this prospective study approved by the local Ethical Committee (Protocol 0018091/18). No inclusion criterion was pre-defined, except for the need for an informed consent signed by the patient. During RALP, one or more samples from the peri-prostatic tissue were retrieved in case of proximity of a mpMRI-lesion or in the case of suspicious ECE based on surgeon's perception; all interventions were performed by a single surgeon (BR).
Specimen were analyzed according to our previously described technique 8 Nineteen out of 20 patient had a localized disease(<=pT2); one had a macroscopical site of ECE, proximal to a PIRADS-5 lesion, recognized intra-operatively. Overall, 2 patients had a positive surgical margin (PSM)(the pT3a, 1 pT2c).
A total of 41 samples from peri-prostatic tissue were immediately available for FCM (median per-patient:2). PCa was detected in 1 (the case of macroscopical pT3a), prostatic benign glands were detected in 1 patient, the remaining cases had only soft tissues.
Extra-prostatic components as fatty tissue (FCM, Fig 1a) , muscle bundles, nerves (FCM, Fig   2a) are basically assessed in the reflectance mode and given in a pink-colored fashion resembling eosin (Figure 1) ; prostate glandular patterns are clearly different, with a predominant purple color given by acridine stained nuclei (FCM, Figure 3a ). PCa is depicted in Figure 4a 
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